OmniSeq Email Format
Biotechnology ResearchNew York, United States11-50 Employees
OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, created as an innovation of Roswell Park Cancer Institute. It uses molecular profiling to help clinicians identify the most appropriate therapies or clinical trials for individual cancer patients. Its clinical offerings include assays that examine genomic and immune markers associated with approved therapies and trials, supporting informed treatment decisions. The company operates in the biotechnology research sector, positioned at the intersection of diagnostics and precision oncology. Its customers include clinicians seeking to tailor cancer treatments and pharmaceutical partners engaged in immuno-oncology research. In 2021, Labcorp announced the acquisition of OmniSeq, marking a notable corporate development in its history.